(ADMA) ADMA Biologics - Ratings and Ratios
Immune Globulin, Hepatitis B, Plasma
ADMA EPS (Earnings per Share)
ADMA Revenue
Description: ADMA ADMA Biologics
ADMA Biologics Inc is a biopharmaceutical company specializing in plasma-derived biologics for treating immune deficiencies and infectious diseases. Its product portfolio includes BIVIGAM and ASCENIV for primary humoral immunodeficiency, and Nabi-HB for Hepatitis B exposure. The company is also developing a pipeline of therapeutics for S. pneumonia infection.
From a business perspective, ADMA Biologics operates its own source plasma collection facilities, which is a critical component of its supply chain, allowing for greater control over raw material sourcing. Its products are sold through various channels, including independent distributors, wholesalers, and specialty pharmacies. As a biotechnology company, its success is heavily dependent on the efficacy and market acceptance of its products, as well as its ability to navigate the complex regulatory landscape.
Key Performance Indicators (KPIs) to watch for ADMA Biologics include revenue growth, gross margin, and research and development (R&D) expenses as a percentage of revenue. The companys return on equity (RoE) of 72.39% indicates a high level of profitability relative to shareholder equity. Additionally, the price-to-earnings (P/E) ratio of 19.92 and forward P/E of 28.99 suggest that the market expects significant earnings growth in the future. Monitoring the companys cash flow from operations and capital expenditures will also be crucial in assessing its financial health and ability to invest in future growth initiatives.
From a technical analysis perspective, the stock is currently trading at $18.59, with support levels at $17.1 and $13.6, and resistance levels at $19.6 and $22.2. The short-term moving averages (SMA20 and SMA50) indicate a potential bullish crossover, although the SMA200 is slightly below the current price, suggesting a neutral long-term trend. The Average True Range (ATR) of 0.59 indicates moderate volatility.
ADMA Stock Overview
| Market Cap in USD | 4,033m |
| Sub-Industry | Biotechnology |
| IPO / Inception | 2013-10-17 |
ADMA Stock Ratings
| Growth Rating | 55.0% |
| Fundamental | 83.4% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | -23.3% |
| Analyst Rating | 4.33 of 5 |
ADMA Dividends
Currently no dividends paidADMA Growth Ratios
| Growth Correlation 3m | -67.4% |
| Growth Correlation 12m | -3.7% |
| Growth Correlation 5y | 90.7% |
| CAGR 5y | 83.54% |
| CAGR/Max DD 3y | 2.34 |
| CAGR/Mean DD 3y | 8.21 |
| Sharpe Ratio 12m | 0.13 |
| Alpha | -16.24 |
| Beta | 0.305 |
| Volatility | 54.87% |
| Current Volume | 3450k |
| Average Volume 20d | 2792.5k |
| Stop Loss | 15.4 (-4.4%) |
| Signal | 0.06 |
Piotroski VR‑10 (Strict, 0-10) 5.0
| Net Income (208.9m TTM) > 0 and > 6% of Revenue (6% = 28.5m TTM) |
| FCFTA 0.12 (>2.0%) and ΔFCFTA -5.73pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 68.46% (prev 78.58%; Δ -10.12pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.14 (>3.0%) and CFO 76.7m <= Net Income 208.9m (YES >=105%, WARN >=100%) |
| Net Debt (-6.46m) to EBITDA (163.1m) ratio: -0.04 <= 3.0 (WARN <= 3.5) |
| Current Ratio 5.33 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (248.6m) change vs 12m ago 2.66% (target <= -2.0% for YES) |
| Gross Margin 53.00% (prev 45.96%; Δ 7.04pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 101.5% (prev 87.74%; Δ 13.71pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 15.23 (EBITDA TTM 163.1m / Interest Expense TTM 10.2m) >= 6 (WARN >= 3) |
Altman Z'' 2.98
| (A) 0.58 = (Total Current Assets 399.6m - Total Current Liabilities 74.9m) / Total Assets 558.4m |
| (B) -0.44 = Retained Earnings (Balance) -247.5m / Total Assets 558.4m |
| (C) 0.33 = EBIT TTM 155.2m / Avg Total Assets 467.4m |
| (D) -1.55 = Book Value of Equity -247.4m / Total Liabilities 160.1m |
| Total Rating: 2.98 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 83.39
| 1. Piotroski 5.0pt = 0.0 |
| 2. FCF Yield 1.65% = 0.82 |
| 3. FCF Margin 13.94% = 3.48 |
| 4. Debt/Equity 0.19 = 2.48 |
| 5. Debt/Ebitda 0.46 = 2.34 |
| 6. ROIC - WACC 97.72% = 12.50 |
| 7. RoE 61.78% = 2.50 |
| 8. Rev. Trend 97.34% = 4.87 |
| 9. Rev. CAGR 48.54% = 2.50 |
| 10. EPS Trend 75.68% = 1.89 |
| 11. EPS CAGR 0.0% = 0.0 |
What is the price of ADMA shares?
Over the past week, the price has changed by -4.51%, over one month by -3.88%, over three months by -25.42% and over the past year by -8.73%.
Is ADMA Biologics a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of ADMA is around 22.09 USD . This means that ADMA is currently undervalued and has a potential upside of +37.12% (Margin of Safety).
Is ADMA a buy, sell or hold?
- Strong Buy: 2
- Buy: 0
- Hold: 1
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the ADMA price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 29.1 | 80.4% |
| Analysts Target Price | 29.1 | 80.4% |
| ValueRay Target Price | 24.3 | 51% |
Last update: 2025-09-04 04:30
ADMA Fundamental Data Overview
CCE Cash And Equivalents = 90.3m USD (Cash And Short Term Investments, last quarter)
P/E Trailing = 19.8824
P/E Forward = 28.9855
P/S = 8.505
P/B = 10.3043
Beta = 0.378
Revenue TTM = 474.2m USD
EBIT TTM = 155.2m USD
EBITDA TTM = 163.1m USD
Long Term Debt = 73.4m USD (from longTermDebt, last quarter)
Short Term Debt = 1.13m USD (from shortTermDebt, last quarter)
Debt = 74.5m USD (Calculated: Short Term 1.13m + Long Term 73.4m)
Net Debt = -6.46m USD (from netDebt column, last quarter)
Enterprise Value = 4.02b USD (4.03b + Debt 74.5m - CCE 90.3m)
Interest Coverage Ratio = 15.23 (Ebit TTM 155.2m / Interest Expense TTM 10.2m)
FCF Yield = 1.65% (FCF TTM 66.1m / Enterprise Value 4.02b)
FCF Margin = 13.94% (FCF TTM 66.1m / Revenue TTM 474.2m)
Net Margin = 44.06% (Net Income TTM 208.9m / Revenue TTM 474.2m)
Gross Margin = 53.00% ((Revenue TTM 474.2m - Cost of Revenue TTM 222.9m) / Revenue TTM)
Tobins Q-Ratio = -16.23 (set to none) (Enterprise Value 4.02b / Book Value Of Equity -247.4m)
Interest Expense / Debt = 2.46% (Interest Expense 1.83m / Debt 74.5m)
Taxrate = -57.24% (set to none) (-72.0m / 125.7m)
NOPAT = unknown (EBIT/Op.Income or Taxrate missing)
Current Ratio = 5.33 (Total Current Assets 399.6m / Total Current Liabilities 74.9m)
Debt / Equity = 0.19 (Debt 74.5m / last Quarter total Stockholder Equity 398.3m)
Debt / EBITDA = 0.46 (Net Debt -6.46m / EBITDA 163.1m)
Debt / FCF = 1.13 (Debt 74.5m / FCF TTM 66.1m)
Total Stockholder Equity = 338.2m (last 4 quarters mean)
RoA = 37.42% (Net Income 208.9m, Total Assets 558.4m )
RoE = 61.78% (Net Income TTM 208.9m / Total Stockholder Equity 338.2m)
RoCE = 37.71% (Ebit 155.2m / (Equity 338.2m + L.T.Debt 73.4m))
RoIC = 97.72% (Ebit 155.2m / (Assets 558.4m - Current Assets 399.6m))
WACC = unknown (E(4.03b)/V(4.11b) * Re(7.14%)) + (D(74.5m)/V(4.11b) * Rd(2.46%) * (1-Tc(none)))
Shares Correlation 3-Years: 90.91 | Cagr: 2.17%
Discount Rate = 7.14% (= CAPM, Blume Beta Adj.) -> floored to rf + ERP 8.05%
[DCF Debug] Terminal Value 70.46% ; FCFE base≈66.1m ; Y1≈43.4m ; Y5≈19.8m
Fair Price DCF = 1.63 (DCF Value 390.1m / Shares Outstanding 238.6m; 5y FCF grow -40.0% → 3.0% )
Revenue Correlation: 97.34 | Revenue CAGR: 48.54%
Rev Growth-of-Growth: -11.66
EPS Correlation: 75.68 | EPS CAGR: 0.0%
EPS Growth-of-Growth: -51.68
Additional Sources for ADMA Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle